{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:33:12Z","timestamp":1792683192004,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clgc.2025.102378","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:11:43Z","timestamp":1747739503000},"page":"102378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3810-3307","authenticated-orcid":false,"given":"Simon U.","family":"Engelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Pickl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-0130","authenticated-orcid":false,"given":"Maximilian","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6547-8515","authenticated-orcid":false,"given":"Felix","family":"Kasparbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rinderknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"K\u00e4lble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Siska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja-Maria","family":"Decking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miodrag","family":"Gu\u017evi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102378_bib0001","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102378_bib0002","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11255-022-03339-6","article-title":"Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case\u2013control matching study","volume":"54","author":"van Ginkel","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clgc.2025.102378_bib0003","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00262-021-02953-0","article-title":"Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer","volume":"71","author":"Schuettfort","year":"2022","journal-title":"Can Immunol, Immunother"},{"key":"10.1016\/j.clgc.2025.102378_bib0004","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0022-5347(05)65348-7","article-title":"Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer","volume":"167","author":"Andrews","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102378_bib0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.14740\/wjon1536","article-title":"Association between interleukin-6 levels and lymph node metastasis in bladder cancer patients","volume":"13","author":"Warli","year":"2022","journal-title":"World J Oncol"},{"key":"10.1016\/j.clgc.2025.102378_bib0006","first-page":"412","article-title":"Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle\u2013invasive bladder cancer","volume":"40","author":"Tong","year":"2022","journal-title":"Urologic Oncol: Sem Orig Investigat"},{"key":"10.1016\/j.clgc.2025.102378_bib0007","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/791212","article-title":"Mechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells","volume":"2013","author":"Tsui","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.clgc.2025.102378_bib0008","first-page":"2","article-title":"IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2025.102378_bib0009","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102378_bib0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2020.06.018","article-title":"Targeting Stat3 signaling impairs the progression of bladder cancer in a mouse model","volume":"490","author":"Korac-Prlic","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clgc.2025.102378_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-45132-2","article-title":"The IL6\/JAK\/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer","volume":"15","author":"Amara","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2025.102378_bib0012","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1043-4666(02)91961-7","article-title":"Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and Cc16 in human serum","volume":"19","author":"Kenis","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.clgc.2025.102378_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.132157.1","article-title":"Correlation of serum interleukin-6 levels and neutrophil-lymphocyte ratio in the severity of COVID-19","volume":"12","author":"Esa","year":"2023","journal-title":"F1000Res"},{"key":"10.1016\/j.clgc.2025.102378_bib0014","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.2147\/IDR.S384351","article-title":"Diagnostic and prognostic value of interleukin-6 in emergency department sepsis patients","volume":"15","author":"Yu","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.clgc.2025.102378_bib0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1053\/plac.2002.0835","article-title":"Secretion of interleukin-1\u03b2 and interleukin-6 by fragments of term human placental villi: signalling pathways and effects of tumour necrosis factor \u03b1 and mode of delivery","volume":"23","author":"Turner","year":"2002","journal-title":"Placenta"},{"key":"10.1016\/j.clgc.2025.102378_bib0016","first-page":"1057","article-title":"Human colon cancer produces a factor which induces the proliferation of venous endothelial cells","volume":"8","author":"Iwasaki","year":"2001","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clgc.2025.102378_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2024.2373519","article-title":"Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism","volume":"13","author":"Eguren-Santamar\u00eda","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clgc.2025.102378_bib0018","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2005.12.003","article-title":"Interleukin-6 level in patients with colorectal cancer","volume":"244","author":"Esfandi","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clgc.2025.102378_bib0019","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12223-011-0018-0","article-title":"Spontaneous in vitro IL-6 production in various intestinal segments in patients with inflammatory bowel disease","volume":"56","author":"Drastich","year":"2011","journal-title":"Folia Microbiol (Praha)"},{"key":"10.1016\/j.clgc.2025.102378_bib0020","unstructured":"Kane SP. Sample size calculator. Clincalc: Available at: https:\/\/clincalc.com\/stats\/samplesize.aspx. Updated June 23, 2024. Accessed May 2, 2025."},{"key":"10.1016\/j.clgc.2025.102378_bib0021","doi-asserted-by":"crossref","first-page":"29820","DOI":"10.18632\/oncotarget.25661","article-title":"Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer","volume":"9","author":"Vainer","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2025.102378_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317697552","article-title":"Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer","volume":"39","author":"Kumari","year":"2017","journal-title":"Tumor Biol"},{"key":"10.1016\/j.clgc.2025.102378_bib0023","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/1078-0432.CCR-23-0798","article-title":"Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in platinum-refractory metastatic urothelial carcinoma: a phase ib\/II open-label, multicenter, randomized umbrella study (MORPHEUS Urothelial Carcinoma)","volume":"29","author":"Drakaki","year":"2023","journal-title":"Clin Can Res"},{"key":"10.1016\/j.clgc.2025.102378_bib0024","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1245\/s10434-018-6706-0","article-title":"Predictive value of CD44 in muscle-invasive bladder cancer and its relationship with IL-6 signaling","volume":"25","author":"Wu","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clgc.2025.102378_bib0025","first-page":"1","article-title":"Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy","volume":"14","author":"Alcantara","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2025.102378_bib0026","doi-asserted-by":"crossref","first-page":"853","DOI":"10.7150\/thno.29553","article-title":"Monoclonal antibody against CXCL1 (HL2401) as a novel agent in suppressing IL6 expression and tumoral growth","volume":"9","author":"Miyake","year":"2019","journal-title":"Theranostics"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T21:14:31Z","timestamp":1752700471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1558767325000783"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102378","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102378"}}